Facilitating the adoption of a new bladder cancer diagnostic test to support the management of urology waiting times post-COVID-19 lockdown

该项目将侧重于引进一种新技术，以协助NHS对泌尿科患者进行分层（以确保对患膀胱肿瘤风险最高的患者进行快速诊断）。在2019冠状病毒病之后，前往NHS泌尿科诊所就诊的患者将无法使用现有工具进行优先处理。Arquer Diagnostics有一种新的膀胱癌检测（adx膀胱），由于它能够以98.7-99%的确定性排除高风险肿瘤，因此可以用于支持患者的分层。那些检测结果为阴性的患者患高风险肿瘤的几率非常低，这意味着他们可以安全地推迟在泌尿科诊所进行侵入性检查，而那些高风险的患者可以优先接受检查。通过该项目，Arquer Diagnostics将部署一个临床小组，以确定最需要这种分层工具的医院，并为在NHS诊断实验室安装该测试提供技术专长。该小组还将向NHS泌尿科医生传播相关的临床和技术信息。这些活动将为NHS提供可靠的分层工具，使所有在COVID-19危机期间被延误的患者都能得到强有力的临床依据，减少那些风险最高的患者面临的延误，使这些高风险肿瘤能够更早被发现，从而改善其结果。额外的资金将允许Arquer设计并开展一项针对50名泌尿科医生和20名膀胱癌患者的调查，以了解使用adx膀胱的愿望和意愿，并了解泌尿科医生和患者对该技术的不同看法。这项调查的结果将使Arquer能够确保测试的可用证据以一种方式呈现，向泌尿科医生和患者展示adx膀胱的最大价值。这将确保当NICE对adx膀胱进行评估时，证据支持这一点，这将促进该技术的最终采用。

This project will focus on the introduction of a novel technology to assist NHS in the stratification of urology patients (to ensure a quick diagnosis of patients at highest risk of having a bladder tumour). In the aftermath of COVID-19, patients presenting to NHS urology clinics will not be able to be prioritised with current tools. Arquer Diagnostics have a new Bladder Cancer Test (ADXBLADDER) which can be used to support the stratification of patients', thanks to its ability to rule out high risk tumours with a 98.7-99% certainty. Those patients with a negative test result have a very low chance of having a high risk tumour meaning they can safely delay having the invasive tests at the urology clinics, whilst those at high risk can be prioritised.Through this project a clinical team will be deployed by Arquer Diagnostics to identify those hospitals most in need of this stratification tool and to provide technical expertise for the installation of the test into NHS diagnostic laboratories. The team will also disseminate the relevant clinical and technical information to the NHS Urologists. These activities will provide NHS with a reliable stratification tool so that all the patients delayed during the COVID-19 crisis will be attended to with a strong clinical rationale, reducing the delay faced by those patients at highest risk, allowing these high risk tumours to be identified earlier and therefore improving their outcome.Additional funding will allow Arquer to design and conduct a survey of 50 urologists and 20 bladder cancer patients to understand the desire and willingness to use ADXBLADDER and to understand how differently urologists and patients view the technology. The results of this survey will allow Arquer to ensure that the evidence available for the test is presented in a way that demonstrates the greatest value of ADXBLADDER to both urologists and patients alike. This will ensure that when ADXBLADDER is assessed by NICE, the evidence supports this, which will facilitate the eventual adoption of the technology,